Quest Diagnostics management check
DGX · Health Care · Health Care Services · CEO James E. Davis
Filings as of
Closest peers in Health Care Services
- 60CICigna80
- 126DVADaVita74
- 208ABBVAbbVie68
- 218DGXQuest Diagnostics67
- 223LHLabcorp66
- 305CVSCVS Health61
The seven checks
- GoodBeat its chosen peers
Have owners done well?
What $100 became since fiscal 2021
6064thDetail
$100 invested at the start of fiscal 2021 grew to $161, against $148 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
8045thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.61 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- n/aNot enough data
What does the CEO cost owners?
——No pay or net income figure for the latest year.
- WatchCEO stake ≈ 1.9 years of pay
Do they own the stock?
122,423 shares ≈ $29.7m
6 mo: ▲ $0 bought · ▼ $23.7m sold
4954thDetail
The CEO holds 122,423 shares, directly or through trusts (unvested awards not counted): about 1.9 years of pay. Light activity: no buys, $23.7m sold in six months. 20 of 20 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares +0.0% a year; flagged above +2%
Stock pay 0.8% of revenue
5035thDetail
Diluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 0.8% of revenue in the latest year.
- Watch2 CEOs in the pay table
Is leadership stable?
3 filings under 8-K 5.02 in 3 years
CEOs: Stephen H. Rusckowski, James E. Davis
6038thDetail
CEOs in the pay table: Stephen H. Rusckowski, James E. Davis. 3 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 6, 2026.
Pay tied most to Adjusted Diluted Earnings Per Share
Other key measuresRevenuePatient Experience/Employee ExperienceCommunity Impact Goals
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | James E. Davis | $15.5m | $26.5m | $3.3m | $161 | $148 | — |
| 2024 | James E. Davis | $14.4m | $24.3m | $3.0m | $137 | $129 | — |
| 2023 | James E. Davis | $12.7m | $9.4m | $2.9m | $123 | $126 | — |
| 2022 | Stephen H. Rusckowski, James E. Davis | $15.7m | $12.7m | $3.4m | $136 | $124 | — |
| 2021 | Stephen H. Rusckowski | $14.6m | $49.2m | $3.4m | $148 | $126 | — |
Insiders and the CEO's stakeQuiet
- CEO and President
- J. E. Davis
- Shares held
- 122,423
- At that filing's price
- ≈ $29.7m
- Latest Form 4
- Sep 1, 2026
Light activity: no buys, $23.7m sold in six months. 20 of 20 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldMichael E PrevoznikSVP & General Counsel · 10b5-1 plan$5.5mAug 28, 2026
- SoldCatherine T. DohertyExecutive Vice President · 10b5-1 plan$5.5mNov 3, 2026
- SoldJ. E. DavisCEO and President · 10b5-1 plan$4.4mSep 1, 2026
- SoldMichael J DeppeSVP, Corp. Controller & CAO · 10b5-1 plan$3.1mNov 13, 2026
Leadership and governance on file
All 14 filings
- Oct 6, 2026Leadership change8-K 5.02
- Mar 12, 2026Leadership change8-K 5.02
- May 21, 2024Leadership change8-K 5.02
- Sep 29, 2023Leadership change8-K 5.02
- Nov 18, 2022Leadership change8-K 5.02
- Nov 1, 2022Leadership change8-K 5.02
- Oct 28, 2022Leadership change8-K 5.02
- Jul 1, 2022Leadership change8-K/A 5.02
- Jun 14, 2022Leadership change8-K 5.02
- May 25, 2022Leadership change8-K 5.02
- Mar 2, 2022Leadership change8-K 5.02
- Mar 1, 2022Leadership change8-K 5.02
- Mar 1, 2022Leadership change8-K/A 5.02
- Feb 3, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 21, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $6.1bn returned to owners in buybacks and dividends, 108% of net income, and $409.0m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $10.8bn | $9.9bn | $9.3bn | $9.9bn | $11.0bn |
| Net income | $2.0bn | $946.0m | $854.0m | $871.0m | $992.0m |
| Stock-based pay | $79.0m | $77.0m | $77.0m | $88.0m | $88.0m |
| Buybacks | $2.2bn | $1.4bn | $275.0m | $151.0m | $450.0m |
| Dividends | $309.0m | $305.0m | $314.0m | $331.0m | $353.0m |
| Diluted shares | 128m | 118m | 113m | 113m | 113m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.